Cargando…
Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels
Type 2 diabetes mellitus (T2DM) constitutes a major portion of Jordan’s disease burden, and incidence rates are rising at a rapid rate. Due to variability in the drug’s response between ethnic groups, it is imperative that the pharmacogenetics of metformin be investigated in the Jordanian population...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462993/ https://www.ncbi.nlm.nih.gov/pubmed/30934600 http://dx.doi.org/10.3390/jpm9010017 |
_version_ | 1783410676813791232 |
---|---|
author | AL-Eitan, Laith N. Almomani, Basima A. Nassar, Ahmad M. Elsaqa, Barakat Z. Saadeh, Nesreen A. |
author_facet | AL-Eitan, Laith N. Almomani, Basima A. Nassar, Ahmad M. Elsaqa, Barakat Z. Saadeh, Nesreen A. |
author_sort | AL-Eitan, Laith N. |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) constitutes a major portion of Jordan’s disease burden, and incidence rates are rising at a rapid rate. Due to variability in the drug’s response between ethnic groups, it is imperative that the pharmacogenetics of metformin be investigated in the Jordanian population. The objective of this study was to investigate the relationship between twenty-one single nucleotide polymorphisms (SNPs) in the SLC22A1, SLC22A2, and SLC22A3 genes and their effects on metformin pharmacogenetics in Jordanian patients diagnosed with type 2 diabetes mellitus. Blood samples were collected from 212 Jordanian diabetics who fulfilled the inclusion criteria, which were then used in SNP genotyping and determination of HbA1c levels. The rs12194182 SNP in the SLC22A3 gene was found to have a significant association (p < 0.05) with lower mean HbA1c levels, and this association more pronounced in patients with the CC genotype (i.e., p-value was significant before correcting for multiple testing). Moreover, the multinomial logistic regression analysis showed that SNP genotypes within the SLC22A1, SLC22A2, and SLC22A3 genes, body mass index (BMI) and age of diagnosis were significantly associated with glycemic control (p < 0.05). The results of this study can be used to predict response to metformin and other classes of T2DM drugs, making treatment more individualized and resulting in better clinical outcomes. |
format | Online Article Text |
id | pubmed-6462993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64629932019-04-19 Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels AL-Eitan, Laith N. Almomani, Basima A. Nassar, Ahmad M. Elsaqa, Barakat Z. Saadeh, Nesreen A. J Pers Med Article Type 2 diabetes mellitus (T2DM) constitutes a major portion of Jordan’s disease burden, and incidence rates are rising at a rapid rate. Due to variability in the drug’s response between ethnic groups, it is imperative that the pharmacogenetics of metformin be investigated in the Jordanian population. The objective of this study was to investigate the relationship between twenty-one single nucleotide polymorphisms (SNPs) in the SLC22A1, SLC22A2, and SLC22A3 genes and their effects on metformin pharmacogenetics in Jordanian patients diagnosed with type 2 diabetes mellitus. Blood samples were collected from 212 Jordanian diabetics who fulfilled the inclusion criteria, which were then used in SNP genotyping and determination of HbA1c levels. The rs12194182 SNP in the SLC22A3 gene was found to have a significant association (p < 0.05) with lower mean HbA1c levels, and this association more pronounced in patients with the CC genotype (i.e., p-value was significant before correcting for multiple testing). Moreover, the multinomial logistic regression analysis showed that SNP genotypes within the SLC22A1, SLC22A2, and SLC22A3 genes, body mass index (BMI) and age of diagnosis were significantly associated with glycemic control (p < 0.05). The results of this study can be used to predict response to metformin and other classes of T2DM drugs, making treatment more individualized and resulting in better clinical outcomes. MDPI 2019-03-25 /pmc/articles/PMC6462993/ /pubmed/30934600 http://dx.doi.org/10.3390/jpm9010017 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article AL-Eitan, Laith N. Almomani, Basima A. Nassar, Ahmad M. Elsaqa, Barakat Z. Saadeh, Nesreen A. Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels |
title | Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels |
title_full | Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels |
title_fullStr | Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels |
title_full_unstemmed | Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels |
title_short | Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels |
title_sort | metformin pharmacogenetics: effects of slc22a1, slc22a2, and slc22a3 polymorphisms on glycemic control and hba1c levels |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462993/ https://www.ncbi.nlm.nih.gov/pubmed/30934600 http://dx.doi.org/10.3390/jpm9010017 |
work_keys_str_mv | AT aleitanlaithn metforminpharmacogeneticseffectsofslc22a1slc22a2andslc22a3polymorphismsonglycemiccontrolandhba1clevels AT almomanibasimaa metforminpharmacogeneticseffectsofslc22a1slc22a2andslc22a3polymorphismsonglycemiccontrolandhba1clevels AT nassarahmadm metforminpharmacogeneticseffectsofslc22a1slc22a2andslc22a3polymorphismsonglycemiccontrolandhba1clevels AT elsaqabarakatz metforminpharmacogeneticseffectsofslc22a1slc22a2andslc22a3polymorphismsonglycemiccontrolandhba1clevels AT saadehnesreena metforminpharmacogeneticseffectsofslc22a1slc22a2andslc22a3polymorphismsonglycemiccontrolandhba1clevels |